Moleculin Biotech Inc. (MBRX)
Moleculin Biotech Statistics
Share Statistics
Moleculin Biotech has 4.16M shares outstanding. The number of shares has increased by 43.25% in one year.
| Shares Outstanding | 4.16M |
| Shares Change (YoY) | 43.25% |
| Shares Change (QoQ) | 12.18% |
| Owned by Institutions (%) | 17.39% |
| Shares Floating | 4.03M |
| Failed to Deliver (FTD) Shares | 6.09K |
| FTD / Avg. Volume | 0.11% |
Short Selling Information
The latest short interest is 169.87K, so 5.32% of the outstanding shares have been sold short.
| Short Interest | 169.87K |
| Short % of Shares Out | 5.32% |
| Short % of Float | 5.5% |
| Short Ratio (days to cover) | 2.62 |
Valuation Ratios
The PE ratio is -0.85 and the forward PE ratio is -0.31. Moleculin Biotech's PEG ratio is -0.18.
| PE Ratio | -0.85 |
| Forward PE | -0.31 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 0.98 |
| P/FCF Ratio | -1.05 |
| PEG Ratio | -0.18 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Moleculin Biotech Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.86, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.86 |
| Quick Ratio | 3.86 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 2.15 |
| Cash Flow / Debt | -41.99 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.14% and return on capital (ROIC) is -111.2%.
| Return on Equity (ROE) | -1.14% |
| Return on Assets (ROA) | -0.78% |
| Return on Capital (ROIC) | -111.2% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1,653,833.33 |
| Employee Count | 18 |
| Asset Turnover | 0 |
| Inventory Turnover | 127K |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -88.66% in the last 52 weeks. The beta is 1.94, so Moleculin Biotech's price volatility has been higher than the market average.
| Beta | 1.94 |
| 52-Week Price Change | -88.66% |
| 50-Day Moving Average | 1.52 |
| 200-Day Moving Average | 2.69 |
| Relative Strength Index (RSI) | 45.09 |
| Average Volume (20 Days) | 5.73M |
Income Statement
| Revenue | n/a |
| Gross Profit | -127K |
| Operating Income | -29.63M |
| Net Income | -29.77M |
| EBITDA | -29.5M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -15.07 |
Balance Sheet
The company has 23.55M in cash and 574K in debt, giving a net cash position of 22.98M.
| Cash & Cash Equivalents | 23.55M |
| Total Debt | 574K |
| Net Cash | 22.98M |
| Retained Earnings | -131.6M |
| Total Assets | 23.39M |
| Working Capital | 6.01M |
Cash Flow
In the last 12 months, operating cash flow was -24.1M and capital expenditures -124K, giving a free cash flow of -24.23M.
| Operating Cash Flow | -24.1M |
| Capital Expenditures | -124K |
| Free Cash Flow | -24.23M |
| FCF Per Share | -12.26 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MBRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1288.03% |
| FCF Yield | -498.21% |
Analyst Forecast
The average price target for MBRX is $8, which is 583.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 583.8% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Mar 22, 2024. It was a backward split with a ratio of 1:15.
| Last Split Date | Mar 22, 2024 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -12.6 |
| Piotroski F-Score | 2 |